

Innovation in fighting infectious disease

Provide complete detection for improved care



Offer comprehensive detection with a complete menu

Only Roche has the broadest infectious disease portfolio available on an integrated platform.

ASSAYS	ANALYZER PLATFORMS			
	e 411	e 601	e 602	e 801
Hepatitis				
Anti-HAV	▪	▪	▪	▪
Anti-HAV IgM	▪	▪	▪	▪
Anti-HBs	▪	▪	▪	ID
Anti-HBc	▪	▪	▪	▪
Anti-HBc IgM	▪	▪	▪	▪
HBsAg	▪	▪	▪	▪
HBeAg			▪	▪
Anti-HBe			ID	ID
Anti-HCV	▪	▪	▪	▪
ToRCH				
Toxo IgG	▪	▪	▪	▪
Toxo IgM	▪	▪	▪	▪
Other Syphilis	▪	▪	▪	▪
Rubella IgG	▪	▪	▪	▪
Rubella IgM	▪	▪	▪	▪
CMV IgG	▪		▪	▪
CMV IgM	▪	▪	▪	▪
HSV 1	▪	▪	▪	▪
HSV 2	▪	▪	▪	▪
HIV				
HIV Combi PT			▪	
HIV Duo				ID


▪ = Available

ID = In development/research only. Product is not available in the United States.

Get a healthy head start in fighting infectious disease

Detect more infectious diseases with greater speed and precision with the Roche assay portfolio, which delivers:

- Broadest infectious disease portfolio on a single analyzer
- Superior efficiency, convenience and performance
- Fastest turnaround time — 18 to 27 minutes
- Small sample volumes



Streamline operations by enhancing core lab functionality.

Arrive at answers sooner with the fastest turnaround times.

TTFR/Incubate Times							
Vendor	Anti-HAV, total (HAV IgG-Abbott)	Anti-HAV IgM	HBsAg	Anti-HBc	Anti-HBc IgM	Anti-HBs	Anti-HCV
Siemens ADVIA Centaur ¹	>52 min	42 min	23 min	>48 min	>48 min	57 min	>41 min
Siemens Immulite ²	Not available	Not available	65 min	60 min	60 min	60 min	Not available
Abbott Architect ³	28 min	28 min	28 min	28 min	28 min	28 min	Not available
Ortho Clinical Vitros ECI ⁴	53 min	43 min	55 min	55 min	53 min	55 min	55 min
Roche	18 min	18 min	18 min	27 min	18 min	18 min	18 min

Enhance convenience with consistently small sample volumes.

Vendor	Anti-HAV, total (HAV IgG-Abbott)	Anti-HAV IgM	HBsAg	Anti-HBc	Anti-HBc IgM	Anti-HBs	Anti-HCV
Siemens ADVIA Centaur ¹	20 uL	20 uL	100 uL	50 uL	15 uL	100 uL	10 uL
Siemens Immulite ²	Not available	Not available	100 uL	50 uL	10 uL Samples must be prediluted in 1 in 21 Anti-HBc Diluent	50 uL	Not available
Abbott Architect ³	75 uL/150 uL	70 uL/150 uL (priority/ <3 hours)	125 uL/150 uL (priority/ <3 hours)	75 uL/ 150 uL	64 uL/150 uL (priority/ <3 hours)	125 uL/150 uL	70 uL/150 uL (priority/ <3 hours)
Ortho Clinical Vitros ECI ⁴	10 uL	10 uL	80 uL	50 uL	10 uL	80 uL	20 uL
Roche	50 uL	10 uL	50 uL	40 uL	10 uL	40 uL	50 uL

Speed treatment decisions with high-performance assays

Because patients with either HCV, syphilis or HIV are more prone to contract all three diseases,⁵ our assays may be run together to help you maximize efficiency and speed diagnosis.

Elecsys® Anti-HCV II assay

The first-line test to aid in the diagnosis of HCV, delivering reliable, accurate results for patient-focused decision-making and a more efficient workflow.

- 100% sensitivity for all genotypes
- Excellent seroconversion sensitivity for early detection of infection
- High specificity in clinical routine testing
- Improve workflow with ready-to-use liquid reagents, lot calibration and 31 days of onboard stability

Elecsys® Syphilis assay

Detect syphilis sooner and throughout its progression with the better treponemal test.

- 100% sensitivity in untreated syphilis across all stages of the disease
- Shortest time to results — 18 minutes
- No prozone effect reduces the risk of false negatives
- Small 10 µL sample volume offers greater convenience

Elecsys® HIV combi PT 4th generation (Ag+Ab test)

Designed for early detection of HIV infection across groups and subtypes.

- Excellent analytical sensitivity of 0.84 ± 0.11 IU/mL
- 100% clinical sensitivity to HIV-1, recognition of all known HIV groups and subtypes
- Excellent reproducibility
- High specificity in samples from clinical routine, pregnancy and pediatric testing (99.94%)

The CDC recommends HCV testing for anyone born between 1945–1965.⁶



Research has proven treponemal testing is more effective in identifying disease in the early and late-latent stages.⁷

Elecsys® ToRCH Panel

Extensive panel provides reliable prenatal screening

During pregnancy or delivery, a mother can pass infections onto her child. That's why early detection and treatment of these infections in expectant mothers is crucial for preventing complications in newborns.⁸

Based on recombinant antigens and specific assay formats such as μ -capture and double antigen sandwich (DAGS), Roche ToRCH assays can be run as a complete panel or individually.



Greater efficiency

Consolidation of ToRCH panel on **cobas**® immunology analyzers



Early detection

Allows early identification of infections that could result in acute congenital infections of the newborn



Fewer confirmation tests and fewer reruns

Highly specific assays



Fast reporting

Results in as little as 18 minutes



What is ToRCH?⁹

ToRCH is an acronym of the five infections covered by the panel:

Toxoplasmosis

Other diseases, including HIV, syphilis and hepatitis B

Rubella (German measles)

Cytomegalovirus

Herpes simplex

Comprehensive detection from Roche

- ✓ Broadest infectious disease assay menu available on an integrated IA system
- ✓ High-performance assays for HCV, syphilis and HIV
- ✓ Complete ToRCH panel

Sources

¹Siemens ADVIA Centaur FDA filing: Anti-HAV Total, P040017C; Anti-HAV IgM, P040018C; HBsAg, P110041C; Anti-HBc, P040004C; Anti-HBc IgM, P030040C; Anti-HBs, P100039C; Anti-HCV, P030056C; <https://www.accessdata.fda.gov> (accessed July 11, 2017).

²Siemens Immulite FDA filing: HBsAg, P010050; Anti-HBc, P010051; Anti-HBc IgM, P010053; Anti-HBs, P010052; <https://www.accessdata.fda.gov> (accessed July 12, 2017).

³Abbott Architect FDA filing: Anti-HAV IgG, K113704; Anti-HAV IgM, K063329; HBsAg, P110029C; Anti-HBc, P080023C; Anti-HBc IgM, P060035C; Anti-HBs, P050051C; Anti-HCV, P050042C; <https://www.accessdata.fda.gov> (accessed July 9, 2017).

⁴Ortho Clinical Vitros ECi FDA filing: Anti-HAV Total, K060678; Anti-HAV IgM, K060770; HBsAg, P000044C; Anti-HBc, P030024C; Anti-HBc IgM, P030026C; Anti-HBs, P000014C; Anti-HCV, P010021C; <https://www.accessdata.fda.gov> (accessed July, 10, 2017).

⁵<https://www.cdc.gov> (accessed July 13, 2017).

⁶Viral Hepatitis, Centers for Disease Control and Prevention, <https://www.cdc.gov/hepatitis/hcv/guidelines.htm> (accessed May 31, 2017).

⁷Binnicker, M.J. (2012). "Which algorithm should be used to screen for syphilis?" *Current Opinion in Infectious Diseases* 25:79–85.

⁸"What Is a ToRCH Screen?" <http://www.healthline.com> (accessed August 14, 2017).

⁹"TORCH" <https://www.labtestsonline.org/understanding/analytes/torch/tab/test> (accessed August 14, 2017).

COBAS and ELECSYS are trademarks of Roche. Other product names and trademarks are the property of their respective owners.

©2018 Roche PP-US-11276-0718

Roche Diagnostics
9115 Hague Road
Indianapolis, IN 46256
www.cobas.com
1-800-779-7616